Core Insights - Intuitive Surgical (ISRG) shares have decreased by 13.5% over the past three months, despite strong procedure growth and the adoption of the da Vinci 5 system in Q4 2025 [1][8] - The company's stock has underperformed compared to peers like Medtronic (MDT) and Johnson & Johnson (JNJ), which saw gains of 5.8% and 22.6% respectively [2] - The key question remains whether the fundamentals of Intuitive Surgical support a hold rating [2] Procedure Growth - Management projects a 13-15% global growth in da Vinci procedures for 2026, driven by U.S. general surgery and international market expansion [3][8] - In 2025, procedures outside the U.S. increased by 23%, making up approximately 35% of global volume, indicating improved market access and training [3] - The full commercial rollout of da Vinci 5 is expected to be a significant catalyst for growth in 2026, with utilization rates increasing [4][8] Platform Performance - The SP platform experienced an 87% growth in procedures in 2025, aided by new U.S. clearances and international uptake [5] - Ion procedures grew by 51% globally, with a focus on deeper penetration of the installed base [5] Competitive Landscape - Medtronic is investing in robotic-assisted surgery but is still early in its adoption curve compared to ISRG [11] - Johnson & Johnson is progressing towards broader robotic offerings, while Stryker has a strong position in orthopedics but is limited in soft-tissue procedures [12] Financial Outlook - Earnings estimates for Intuitive Surgical for 2026 have increased by 7% to $10.03 per share, and for 2027 by 5.6% to $11.40, indicating bullish sentiment [13] - The company anticipates gross margins of 67-68% for 2026, facing headwinds from tariffs and a higher mix of da Vinci 5 systems [14][18] Valuation - Intuitive Surgical is currently trading at a forward P/E ratio of 48.68X, which is lower than its five-year median of 71.27X but significantly higher than the industry average of 26.96X [18] Investment Recommendation - The fourth-quarter performance and 2026 outlook support a high-quality growth narrative for Intuitive Surgical, driven by procedure expansion and platform innovation [19] - Despite margin pressures, the company's scale and clinical leadership position it well for long-term value compounding [20]